Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 5;14(3):e12404.
doi: 10.1002/pul2.12404. eCollection 2024 Jul.

Characteristics and risk profiles of patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension living permanently at >2500 m of high altitude in Ecuador

Rodrigo Hoyos  1 , Mona Lichtblau  2 , Elizabeth Cajamarca  1 , Laura Mayer  2 , Esther Irene Schwarz  2 , Silvia Ulrich  2
Affiliations

Characteristics and risk profiles of patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension living permanently at >2500 m of high altitude in Ecuador

Rodrigo Hoyos et al. Pulm Circ. .

Abstract

Over 80 Mio people worldwide live >2500 m, including at least as many patients with pulmonary vascular disease (PVD), defined as pulmonary arterial or chronic thromboembolic pulmonary hypertension (PAH/CTEPH), as elsewhere (estimated 0.1‰). Whether PVD patients living at high altitude have altered disease characteristics due to hypobaric hypoxia is unknown. In a cross-sectional study conducted at the Hospital Carlos Andrade Marin in Quito, Ecuador, located at 2840 m, we included 36 outpatients with PAH or CTEPH visiting the clinic from January 2022 to July 2023. We collected data on diagnostic right heart catheterization, treatment, and risk factors, including NYHA functional class (FC), 6-min walk distance (6MWD), and NT-brain natriuretic peptide (BNP) at baseline and at last follow-up. Thirty-six PVD patients (83% women, 32 PAH, 4 CTEPH, mean ± SD age 44 ± 13 years, living altitude 2831 ± 58 m) were included and had the following baseline values: PaO2 8.2 ± 1.6 kPa, PaCO2 3.9 ± 0.5 kPa, SaO2 91 ± 3%, mean pulmonary artery pressure 53 ± 16 mmHg, pulmonary vascular resistance 16 ± 4 WU, 50% FC II, 50% FC III, 6MWD 472 ± 118 m, BNP 490 ± 823 ng/L. Patients were treated for 1628 ± 1186 days with sildenafil (100%), bosentan (33%), calcium channel blockers (33%), diuretics (69%), and oxygen (nocturnal 53%, daytime 11%). Values at last visit were: FC (II 75%, III 25%), 6MWD of 496 ± 108 m, BNP of 576 ± 5774 ng/L. Compared to European PVD registries, ambulatory PVD patients living >2500 m revealed similar blood gases and relatively low and stable risk factor profiles despite severe hemodynamic compromise, suggesting that favorable outcomes are achievable for altitude residents with PVD. Future studies should focus on long-term outcomes in PVD patients dwelling >2500 m.

Keywords: hypobaric hypoxia; pulmonary arterial hypertension; pulmonary vascular disease; risk stratification.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Alluvial plot demonstrating the change in the four‐strata risk assessment from the time of diagnosis to the last follow‐up.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano‐Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke‐Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S, ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022;43(38):3618–3731. - PubMed
    1. Ulrich S, Fischler M, Speich R, Bloch KE. Sleep‐related breathing disorders in patients with pulmonary hypertension. Chest. 2008;133:1375–1380. - PubMed
    1. Ulrich S, Keusch S, Hildenbrand FF, Lo Cascio C, Huber LC, Tanner FC, Speich R, Bloch KE. Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre‐capillary pulmonary hypertension and sleep‐disturbed breathing: randomized, double‐blind, cross‐over trial. Eur Heart J. 2015;36:615–623. - PubMed
    1. Ulrich S, Hasler ED, Saxer S, Furian M, Müller‐Mottet S, Keusch S, Bloch KE. Effect of breathing oxygen‐enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham‐controlled cross‐over trial. Eur Heart J. 2017;38:1159–1168. - PubMed
    1. Schneider S, Lichtblau M, Furian M, Mayer L, Berlier C, Müller J, Saxer S, Schwarz E, Bloch K, Ulrich S. Cardiorespiratory adaptation to short‐term exposure to altitude vs. normobaric hypoxia in patients with pulmonary hypertension. J Clin Med. 2022;11:2769. - PMC - PubMed